Method of treating psoriasis vulgaris

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. That is ensured by a therapy involving a combination of the hepatoprotector Phosphogliv and an external non-hormonal therapy. Phosphogliv is prescribed according to the schedule: 2.5 mg intravenously once a day for 10 days, then orally 1 capsule 3 times a day; and the non-hormonal preparation is Cinocap cream 3 times a day; the therapeutic course makes 4 weeks.

EFFECT: invention enables reducing a risk of complications and side effects and prolongs remission ensured by anti-inflammatory, hypolipidemic, immunomodulatory action of the prescribed preparations.

 

The invention relates to medicine, namely to dermatology, and can be used for the treatment of patients vulgar psoriasis.

Currently, researchers consider psoriasis as a systemic chronic multifactorial disease with a primary lesion of the skin, leading autoimmune component in the pathogenesis. Of great importance in the pathogenesis of psoriasis belongs to disturbances in the immune system: an imbalance of T-cell system, the increase in the content of circulating immune complexes, and activation of macrophages and proinflammatory cytokines (TNF-α, IL-1α, IL-2, IL-6, IL-8). Currently, it is known that patients with psoriasis are significantly more likely than the average in the population, identify hyperlipidemia caused by increased concentrations of triglycerides, cholesterol and low density lipoprotein. Using the method of immunofluorescence is shown that oxidized low-density lipoproteins in large quantities accumulate in psoriatic plaques ("Clinical Dermatology". A guide for physicians edited Skripkin J.K. and Butova YU.S., M., 2009, s).

Also psoriasis is characterized by multifactorial Genesis on the background of genetic predisposition, neurogenic, immunological changes and metabolic disorders, including the defeat of the endocrine glands, gastrointestinal Proc. of the KTA, including the liver. Thus, in patients with psoriasis were found to increase the activity of liver enzymes, cholesterol, reducing the antitoxic function of the liver, the imbalance of bile acids. In addition, comorbidities hepatobiliary system often complicates the course of psoriasis, especially in patients with hepatitis who have psoriasis has a more severe course and haste therapy (Skin and venereal disease. A guide for physicians. In 2 volumes. Edited Ukicriminal, Vinmoldova. 1999, str).

The morphological nature of psoriasis is hyperproliferative epidermal cells, disorders of keratinization, and inflammatory reaction in the dermis due to deficiencies in the system of camp/cGMP, pathognomonic changes in the basal layer of the capillaries in the form of loosening and turnaround. In addition there is a violation of the barrier function of the skin, in particular the hydrolipid mantle. It preserves the integrity of the stratum corneum, limiting the penetration into the skin of bacteria, viruses, fungi, preventing the development of infectious and inflammatory processes. (Yevgenyevich, Nov. Modern approaches to improving clinical effectiveness of therapy and rehabilitation of patients with atopic dermatitis, chronic eczema and psoriasis.// Clinical dermatology and venereology. - 2011. No. 2 - p.76).

The traditional method of treatment of psoriasis, including detoxifying, antisense, antihistamines, vitamin preparations and tools for external therapy. The effectiveness of traditional therapy is low, especially in cases of widespread, severe, long-term course of the disease and remains an actual problem of dermatology ("Modern methods of treatment of psoriasis" methodical recommendations under the editorship of Prof. Skripkin J.K., M., 1995, p.3; Yakubovich A.I., Korepanov, A.R., Novitskaya N.N., Chuprin AU Clinical efficacy of gamma Parian in treatment and care of psoriasis patients // journal of dermatology and venereology. - 2009. No. 10(1). - p.31).

Methods of modern systemic therapy of psoriasis (cytostatics, PUVA therapy, retinoids) while effective, but have a large number of adverse reactions, including adverse effects on liver function. To reduce the risk of development of side effects systemic therapy is recommended in combination with various drugs that possess hepatoprotective property: lipoic acid, siripur, Kars, LIV-52 and others, but their effects on lipid metabolism ineffective. Given the characteristics of modern psoriasis, justified is the use in the treatment of disease agents is s, with membraneactive property and the ability to correct dyslipidemia changes (Archakov A.I., Seltsovsky FP and other Phosphogliv: mechanism of action and efficacy in the clinic. Questions medicinal chemistry 2002; 48(2): 139-151).

The closest is a method of treatment of chronic dermatoses, including the use of the hepato - Phosphogypsum in combination with the use of integrated traditional therapies known means, such as vitamins, antihistamines and antisense drugs, local (non-hormonal) means ointments, lotions etc). Phosphogliv appoint a rate of 0.3 mg of phospholipids and glycyrrhizic acid (2 capsules) 3 times a day after meals or disposable injection (RU, patent No. 2196585, MCP AC 31/685, AK 31/704, OR 17/02, publ. 20.01.2003,) prototype.

This method of treatment allows you to treat chronic dermatoses such as psoriasis, atopic dermatitis, eczema and keratodermia, however, therapeutic efficacy of treatment of patients vulgar psoriasis is not high enough.

The objective of the invention is to increase therapeutic efficacy of treatment of patients vulgar psoriasis.

The technical result of the invention is achieved in that in the method of treatment of vulgar psoriasis combination of hepatoprotectors drug - Phosphogliv and outer is not hormonales therapy, Phosphogliv prescribed under the scheme: 2.5 mg intravenously 1 time a day for 10 days, then the transition to oral application of 1 capsule 3 times a day, and as a non-hormonal drug use cream Zanocap 2-3 times a day. Course 1 of treatment is 4 weeks.

The invention consists in the appointment of a drug from the group of hepatoprotectors in combination with topical treatment product that contains zinc pyrithione activated.

For drugs that have aimed pathogenetic action should include Phosphogliv - new domestic hepatoprotector containing phospholipid (phosphatidylcholine) plant origin and sodium salt of glycyrrhizic acid. Phosphatidylcholine is the major structural component of the phospholipid layer of biological membranes, restores the structure and function of damaged membranes of hepatocytes, thanks prevents loss of cells, enzymes and other active substances, normalizes protein, lipid and fat metabolism, restores the detoxification function of the liver, inhibits the formation of connective tissue of the liver, reduces the risk of fibrosis and cirrhosis. Sodium glycyrrhizinate suppresses the reproduction of the virus in the liver and other organs by stimulating the production of g-interferon enhances phagocytosis, increases the act shall want to make natural killer cells and that is especially important in dermatological practice, has anti-inflammatory, immunomodulatory effects and other pharmacokinetic Study characteristics Phosphoglive was carried out in the Institute of biomedical chemistry of the RAMS.

Zanocap (active substance - perion zinc), developed by Russian company OJSC "Pharmstandard". Pharmacological effects of pyrithione are very diverse. Based antimicrobial and antifungal activity is its ability to interact with phospholipid membranes of microbial cells, which leads to a violation of its integrity and ultimately to the death of the microorganism. (Dinning A.J., Al-Adham I.S.I., Austin P. and others Pyrithionebiocide interactions with bacterial phospholipid head groups. J. appl micribiol 1998; 85:1:132-214).

Another equally important feature of pyrithione is its anti-inflammatory activity and participation in the regulation of apoptosis (protogenoi action). Due to the activation of the apoptosis of inflammatory infiltrate achieved a significant reduction in the number of cells as effectors of inflammation, which leads to the reduction of clinical manifestations. In the clinical aspect is very important is the ability pyrithione zinc to inhibit the synthesis of inflammatory cytokines and block from mast cells histamine causing itching of the skin. (Skripkin J.K. Enable the bath pyrithione. The mechanism of action. Clinical application. Rosalila. Journe. 2007; 3, 70-75).

The purpose Phosphoglive scheme: 2.5 mg intravenously 1 time a day for 10 days, then the transition to oral application of 1 capsule 3 times a day, in combination with non-hormonal drug cream Zanocap 2-3 times a day, the course of treatment is 4 weeks, reduces side effects, complications, more quickly achieve clinical remission and reduce the dose of hepatoprotector, i.e. to increase therapeutic efficacy of treatment of patients vulgar psoriasis.

From the analysis of scientific-technical and patent literature inventive combination of properties, leading to a significant increase in therapeutic efficacy by dose reduction, reducing the number of intravenous injections of a complex influence on the basic mechanisms of disease pathogenesis, reduce the duration of exacerbations, prevent side effects and prolongation of remission, is not revealed, which allows to make a conclusion on the conformity of the proposed technical solution the criteria of "novelty" and "inventive step".

The method is as follows.

Patients with psoriasis vulgaris, a disease duration of more than 3 years or exacerbation of 1 month, the size of PASI 20-30 points to clinical examination, clinical expertise is the W, study of the levels of aspartate aminotransferase (ACT), alanine aminotransferase (ALT). The absence of contraindications allows combination therapy that includes the use of traditional methods in combination with hepatic and use external preparation containing zinc pyrithione.

Hepatoprotector (Phosphogliv) is prescribed as follows: 2.5 mg 1 time per day intravenously, then switch to oral form 1 capsule 3 times a day and at the same time assign external preparation containing zinc pyrithione activated (cream Zanocap) 2-3 times per day. The General course of this therapy is 4 weeks.

The proposed method of treatment easily reproducible, affordable and feasible in health care institutions.

Example 1.

Patient I., aged 26, arrived in the dermatology Department of Arnieboy complaining common rash, peeling and mild itching during the day. History: suffering from psoriasis for 8 years autumn and spring exacerbations. Self-treatment for external funds is insignificant. The duration of this exacerbation of 3 months. The traditional clinical examination, the indicator AST increased 3 times, Alat increased in 2 times, PASI - 33.2, DLQI - 20, clinical assessment itching moderately expressed. Assigned to the proposed method of treatment: combined Arabia using traditional methods of treatment and hepatoprotector (phosphoglive) under the scheme, external preparation containing zinc pyrithione (cream zanocap) for 4 weeks.

On the background of the treatment on the 14th day of treatment showed reduction of hyperemia elements, light infiltration in the lower extremities and minor scales, subjective - no itching. PASI - 4.3, DLQI - 10.

Example 2.

Patient I., 69 years old, was admitted to the hospital with complaints of widespread rash, dry skin, minor peeling, mild itching during the day. History: first became ill in 1994. After suffering emotional stress, in subsequent exacerbations in fall and winter. Inpatient treatment was performed 1 time in 2 years, remission was 2-3 months. This aggravation is 2 months, self-treatment for external funds with a small positive dynamics. The traditional laboratory study, hepatic enzymes increased in 1.5 times, PASI - 15,2, DLQI - 14.

Treatment according to the developed scheme: combination therapy with conventional treatment and hepatoprotector (phosphoglive) under the scheme, external - preparation containing zinc pyrithione (cream zanocap) for 4 weeks.

On the 2nd week was a decrease itching, infiltration of elements, a slight peeling was preserved only on the lower extremities.

Tolerability was UD is platonically, no adverse events were noted.

This scheme was applied in the treatment of 30 patients vulgar psoriasis.

Comparative data of the invention are shown in table 1.

Table 1
The proposed methodThe known method
1. The period of treatment, weeks3-4 weeks4-6 weeks
2. Efficiency
treatment:
- clinical79,8%55,7%
recovery
- significant20,2%22,2%
improvement
- improvement-22,1%
3. Duration7-8 months 4-5 months
period of remission
4. Side effectsnoToxic-allergic reactions (data Arnieboy), pruritus

As can be seen from the table, the proposed course of treatment can reduce the duration of stay of the patient in the hospital, when using combination therapy, to achieve a lengthening of the period of remission due to the impact on pathogenetically significant factor vulgar psoriasis. In addition, the proposed method of treatment allows for the treatment of psoriasis patients in inpatient and outpatient settings, with obvious clinical effect, supported by clinical indicators, preventing complications, reducing length of stay of patients in hospital and increasing the length of remission compared with existing treatment methods.

The use of traditional methods of treatment in combination with hepatoprotective and zinc pyrithione drugs provides anti-inflammatory, hypolipidemic, immunomodulatory effect, which represents a therapeutic effect on a number of important components in the pathogenesis of vulgar psoriasis and identified comorbidity.

The method of treatment vulgar psoriasiscialis hepatoprotective drug - Phosphogliv and outer non-hormonal therapy, characterized in that Phosphogliv prescribed under the scheme: 2.5 mg intravenously 1 time a day for 10 days, then the transition to oral application of 1 capsule 3 times a day, and as a non-hormonal drug use cream Zanocap 3 times a day, the course of treatment is 4 weeks.



 

Same patents:

FIELD: medicine.

SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.

EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.

4 ex

FIELD: medicine.

SUBSTANCE: method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. For this purpose, a patient is exposed to narrow-band medium-wave ultraviolet (UV therapy) at wave length 311 nm. It is combined with introducing liptonorm 10 mg once a day for 21-28 days. The UV therapeutic course makes 10 procedures.

EFFECT: method provides fast and prolonged clinical remission of the disease, as well as reduced side effects of the therapy due to the specified UV exposure mode and liptonorm introduction ensuring high photosensitising effect.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to solid forms of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulphonylethyl]-4-acetylaminoisoindoline-1,3-dione of formula (I) inhibiting TNF-α or PDE4 production that enables using them in treating psoriasis.

EFFECT: producing an agent for treating psoriasis.

36 cl, 14 tbl, 33 dwg, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pharmaceutical composition for local application containing fusidic acid within the range of 1 wt % to 5 wt % and mometasone within the range of 0.05 wt % to 2 wt % and a pharmaceutically acceptable carrier to be applied in treating or preventing inflammatory dermatoses caused by a secondary bacterial infection in a patient.

EFFECT: invention provides effective elimination of secondary bacterial infections in dermatologic injuries.

11 cl, 8 ex, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I) and its pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability, to a based pharmaceutical composition, to application thereof in preparing a drug compound and to a combined preparation containing the presented compounds and the other active compound (I) in effective amounts wherein both groups G1 mean CRC, G2 mean a nitrogen atom or group CRd, of the groups G3 and G4 mean a nitrogen atom and the other one means group CH, M means a hydrogen atom or a pharmaceutically acceptable cation, while R1, R2, Ra, Rb, Rc and Rd have the values specified in the patent claim.

EFFECT: preparing pharmaceutically acceptable salts possessing dihydroorotate dehydrogenase inhibitory ability.

25 cl, 115 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining said salts, to pharmaceutical composition, containing said salts, and to application of salt for preparation of medication for treatment, prevention or relief of one or several symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma of physical effort, allergic rhinitis, atopic dermatitis, contact hypersensitivity and hyper IgE syndrome.

EFFECT: invention relates to novel pharmaceutically acceptable salts, containing pharmaceutically acceptable amine, selected from ethylenediamine, piperazine, benzathine or choline and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5yl}acetic acid.

43 cl, 21 dwg, 4 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel crystalline forms I, II and amorphous form of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid.

EFFECT: invention relates to pharmaceutical composition, containing crystalline form I of compound and to application of crystalline form I for treatment, prevention or relief of one or more symptoms of disease, mediated by CRTH2, associated with eosinophils, basophils, where disease is selected from asthma, allergic asthma, asthma, induced by physical effort, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity.

16 cl, 11 dwg, 8 tbl,11 ex

FIELD: medicine.

SUBSTANCE: what is described is a composition for topical application which contains a continuous phase and at least one disperse phase with said composition containing at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue.

EFFECT: composition is characterised by better skin penetration or better stability.

27 cl, 3 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: method of treating psoriasis. The invention refers to medicine, specifically to dermatology, and may be used for treating the patients suffering psoriasis. That is ensured by conducting detoxification, hyposensitising therapy, prescribing antihistamine preparations, vitamins, cytostatics, physiotherapeutic therapy, ointment applications. The conducted therapy is combined with additionally prescribed oral 40% alcoholate (1:10) containing herbal phytoecdysteroids in mass fractions 50 drops 3 times a day 15 minutes before meal daily for 30 days: Rhaponticum carthamoides roots and rhinzomes - 3, pot marigold blossom - 1, wild camomile blossom - 1.

EFFECT: method enabled considerably improved therapeutic effect in the patients due to evident immunomodulating, adaptogenic, sedative and anti-inflammatory effects of herbal phytoecdysteroids.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology and can be applied for external treatment of psoriatic onychodystrophy. For this purpose mixture of gel tisol and ointment daivonex is applied on nidus of affection in ratio 1:2 with following keeping under adhesive plaster during 8-10 h two times per day. Course of treatment constitutes not less than 14 days.

EFFECT: method ensures reduction of treatment terms and duration of remission and obtaining high therapeutic effect.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and deals with complex immunomodulator for prevention of malfunctions and regulation of immune system functioning (versions). Claimed is complex medication for prevention of malfunctions and regulation of immune system functioning, which is characterised by the fact, that it is made in form of capsules and contains human recombinant interferon of alpha, and/or beta, and/or gamma types, retinol palmitate, zinc sulphate monohydrate, additional substance - to 0.1 g. Also claimed is complex immunomodulator for prevention of malfunctions and regulation of immune system functioning, which is characterised by the fact that it is made in form of suppository on hydrophilic base and contains human recombinant interferon of alpha, and/or beta, and/or gamma types, retinol palmitate and/or substances, selected from a number of alpha, beta, gamma carotenes, zinc sulphate monohydrate, as well as additional substances.

EFFECT: invention insures extension of possibilities of prevention and correction of immunological malfunctions in healthy and ill people.

6 cl, 8 ex, 8 tbl

Nootropic agent // 2475250

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an agent exhibiting nootropic action. The declared agent contains calcium chloride, sodium chloride, ferric sulphate (II), zinc sulphate, chromium chloride (III) and potassium bromide in certain proportions.

EFFECT: invention provides normalisation of the CNS function ensured by nootropic action.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. The preparation metallosuccinate 10 ml is introduced intramuscularly three times before calving and two times after every 10 days.

EFFECT: method is effective for correction of the immunobiochemical status in ante- and postpartum cows, preventing reproduction pathologies and producing high-resistant newborn calves.

2 tbl, 1 ex

Antihypoxic agent // 2472503

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is an antihypoxic agent differing by the fact that it represents a complex compound of divalent zinc substituted by 3-hydroxypyridine and diorganodichalcogenide - hexakis(3-hydroxy-2-ethyl-6-methylpyridinato)[tris(dibenzylselenido)dizinc(P)pentadeca-semihydrate of formula [Zn(II)]2A6B3·15.5H2O (the same πQ1983). [Zn(II)]2A6B3·15.5H2O wherein A: B:

EFFECT: efficacy of the reference antihypoxants (antisol, bemityl) is significatly second to πQ1983 by all resistance criteria to acutely developing hypoxia; unlike the reference antihypoxants, πQ1983 is still effective after the intake; reduces rectal temperature, slows down heart rate, reduces respiratory rate and depth, as well as body oxygen consumption; prolongs a period of cortex activity in acutely developing hypoxic condition.

4 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a galvanic particle consisting of zinc, partially copper-plated. A galvanic particle size is equal to nm to 100 mcm, while copper weight therein makes 0.01-10 % of particle weight. The galvanic particles under the invention may be prepared by contact of the zinc particles and a copper salt solution. The invention also refers to a pharmaceutical composition which contains an effective amount of said galvanic particles and a bioabsorbed polymer, and to an oral dosage form containing an effective amount of the galvanic particles under the invention, and a pharmaceutically acceptable carrier. The invention also refers to a method for destruction of drug-resistant microorganisms involving contact of a microorganism and the composition containing the carrier and said galvanic particles.

EFFECT: invention provides preparing galvanic pairs applicable for drug delivery.

16 cl, 19 tbl, 20 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmacological industry and medicine, and concerns an agent for local application effective for treating inflammatory oral diseases of various aethiologies. The agent for treating inflammatory oral diseases contains a hydrophilic base presented by organic silicon glycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O or organic titanium silicone 2Si(C3H7O3)4·Ti(C3H7O3)4·22C3H8O3·88H2O, or water-soluble dimethyl silicone glycerolates (CH3)2Si(C3H7O3)2·xC3H8O3 (0,5≤x≤1); and an active therapeutic additive presented by galavit or polyoxydonium, or betaleukin, or a mixture of oil solution of vitamin E and zinc ingredient under certain proportions. A method of treating inflammatory oral diseases consists in the fact that antiseptic treatment of an involved area is followed by the introduction of said agent by application on oral mucosa or gingival surface or instillation into gingival pockets once a day for 15 min; the therapeutic course is 5-7 days. The presented agent is an accessible form for local application; it enables achieving a high therapeutic effect.

EFFECT: transcutaneous activity of the hydrophilic base enables both using low concentrations of the active therapeutic additive, and ensures deeper penetration into involved tissues.

2 cl, 12 ex

FIELD: medicine.

SUBSTANCE: claimed is application of carbon-containing nanoparticles, representing carbon nanocapsule 10 nm in size, containing iron particles, for destructuring atherosclerotic lesions, formed on the walls of blood vessels. It is demonstrated that claimed carbon-containing nanoparticles, applied on the surface of atherosclerotic lesion, are capable of penetrating into its internal layers and modifying its structure: presence of nanoparticles in it combines with presence in it of segments of sparse collagen structures.

EFFECT: invention can be used for creation of novel efficient medication which makes it possible to destructure atherosclerotic lesions, formed on the walls of blood vessels.

4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition possessing analgesic, anti-inflammatory and locomotor function improving action. The composition contains 1-20 wt % of glucosamine sulphate, 1-10 wt % of chondroitin sulphate, 0.0001-10 wt % of methylsulphonylmethane, 0.01-5 wt % of L-proline, ascorbic acid, magnesium. The declared composition additionally contains zinc gluconate, citric acid, a sweetening agent, a flavour, a preserving agent and water.

EFFECT: composition is presented in the liquid form and possesses improved bioavailability and extended pharmacological action.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, and concerns a combined therapeutic agent possessing antituberculous action. The agent is presented in a solid dosage form which contains a combination of paraaminosalicylic acid and a zinc-containing compound as an active principle, and pharmaceutically acceptable excipients. The zinc-containing compound is specified in zinc picolinate, zinc citrate, zinc acetate, zinc glycerate, zinc monomethionine, zinc aspartate, zinc hyaluronate, zinc gluconate, zinc bisvinylimidazole diacetate, zinc oxide.

EFFECT: composition is characterised by high efficacy.

8 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents composition, which possesses adaptogenic, general tonic and working capacity-increasing action, which contains nicotineamide, alfa-tocopherol acetate, pyridoxine hydrochloride, riboflavin beta-carotene, folic acid, biotin, cyanocarbolomine, coenzyme Q10, potassium hydrogen orthophosphate, inositol, choline, soy lecithin, zinc gluconate, calcium pantothenate, thiamine hydrochloride, vitamin D, fructose, citric acid, ascorbic acid, preservative, sweetener, fragrance, water, components in composition being in specified weight ratio.

EFFECT: invention ensures increase of work capacity and endurance.

7 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dietology, and may be used for preventing and treating overweight and obesity. For this purpose, with underlying diet therapy involving a dietary intake of holy thistle germs, products with minimum animal fat and eliminating cereal products, alcohols and sugar, drug-induced care with rosehip tincture, lecithin, and lactulose, massage manipulations are performed including regular abdominal massage followed by vacuum cup massage and honey massage.

EFFECT: method enables systematic overweight reduction within a comprehensive approach to a problem ensured by a sequence developed by the applicant.

2 ex, 9 cl

Up!